The Rationale of Targeting Neutrophils with Dapsone during Glioblastoma Treatment

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 16, 12 Issues, 2016

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

The Rationale of Targeting Neutrophils with Dapsone during Glioblastoma Treatment

Anti-Cancer Agents in Medicinal Chemistry, 11(8): 756-761.

Author(s): Richard E. Kast, Angelika Scheuerle, Christian R. Wirtz, Georg Karpel-Massler and Marc-Eric Halatsch.

Affiliation: Department of Psychiatry, University of Vermont, 22 Church Street, Burlington, VT 05401, USA.


Data from past research is presented showing that neutrophils are active participants in new vessel formation in normal physiology, in proliferating human endometrium, in non-cancer pathologies as in the pannus of rheumatoid arthritis, and in various cancers, among them glioblastoma. These data show that interleukin-8 (IL-8) is a major chemokine attracting neutrophil infiltrates in these states. Since the old anti-Hansens disease drug dapsone inhibits neutrophil migration along an IL-8 gradient towards increasing concentrations, and is used therapeutically for this attribute to good effect in dermatitis herpetiformis, bullous pemphigoid and rheumatoid arthritis, we suggest dapsone may deprive glioblastoma of neutrophil-mediated growth promoting effects. We review past research showing that vascular endothelial growth factor, VEGF, is carried predominantly intracellularly within neutrophils- only 2% of circulating VEGF is found free in serum. Based on the available evidence summarized by the authors, dapsone has a strong theoretical potential to become a useful anti-VEGF, anti-angiogenic agent in glioblastoma treatment.


Angiogenesis, chemotaxis, chemotherapy, dapsone, glioblastoma, neutrophils, temozolomide, vascular endothelial growth factor, IL-8, azurophilic granules.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 11
Issue Number: 8
First Page: 756
Last Page: 761
Page Count: 6
DOI: 10.2174/187152011797378805
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science